Baker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing.
Meanwhile, the quarter-end position value increased by $295.48 million, reflecting both share purchases and stock price appreciation.
Post-trade, the fund holds 1,126,488 shares valued at $332.02 million.
On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.
According to a recent SEC filing, Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during the fourth quarter of 2025. The estimated value of the transaction is $81.38 million, calculated using the period’s average closing price. The post-trade stake stood at 1,126,488 shares, with the quarter-end valuation up by $295.48 million due to both trading activity and price movements.
| Metric | Value |
|---|---|
| Price (as of market close 2/17/26) | $328.04 |
| Market capitalization | $7 billion |
| Revenue (TTM) | $7.46 million |
| Net income (TTM) | ($273.04 million) |
Praxis Precision Medicines is a Boston-based biotechnology company focused on advancing therapies for neurological and psychiatric disorders with significant unmet medical need. The company leverages a robust pipeline of differentiated clinical candidates targeting neuronal imbalance, supported by strategic collaborations and licensing agreements. Its approach aims to deliver first-in-class or best-in-class treatments, positioning Praxis as a potential leader in the CNS therapeutics market.
Praxis is moving from development stage volatility toward potential commercialization, and that shift often creates the widest dispersion in outcomes, but Baker Bros. seems confident in the firm, and there are certainly reasons to be.
Two NDAs were submitted in early 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic
encephalopathies. Management believes four late-stage assets collectively represent more than $20 billion in revenue potential. And on top of that, the balance sheet is not in a fragile position. Praxis ended 2025 with $926.1 million in cash and investments, and an additional $621 million from a January 2026 offering is expected to fund operations into 2028.
The spending, meanwhile, reflects ambition. Research and development expenses reached $267.1 million for 2025, with a full-year net loss of $303.3 million.
Within a portfolio dominated by multibillion-dollar oncology positions, a roughly 2% allocation is meaningful but not outsized. Long-term investors should focus on regulatory timelines, launch execution, and whether epilepsy data in the first half of 2026 reinforce the thesis. An over 300% stock move prices in optimism, and though, approval and clean commercialization could justify it, delays or bad surprises would not.
Before you buy stock in Praxis Precision Medicines, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Praxis Precision Medicines wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BeOne Medicines Ag and Incyte. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
